Fluoxetine

Drug Profile

Fluoxetine

Alternative Names: LY 110140; Prozac; Prozac Weekly; Reneuron; Sarafem

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eli Lilly
  • Class Antidepressants; Eye disorder therapies; Propylamines; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bulimia nervosa; Major depressive disorder; Obsessive-compulsive disorders; Panic disorder; Premenstrual dysphoric disorder
  • Discontinued Dysthymic disorder; Post-traumatic stress disorders

Most Recent Events

  • 01 Mar 2015 Eli Lilly completes a phase III extension trial in Major depressive disorder in Japan (NCT01808651)
  • 01 Jul 2014 Eli Lilly completes a phase III trial in Major depressive disorder in Japan (NCT01808612)
  • 01 Oct 2013 Warner Chilcott has been acquired and merged into Actavis Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top